Color
Text Size
08/01/2019
The Théa Group has announced the appointment of Ms. Susan Benton as Country Manager for the US entity, Thea Pharma Inc.
Ms. Benton is a senior executive with more than 25 years of global commercial and business development experience in ophthalmic pharmaceuticals. She most recently served at Shire Plc as the Head of Strategy and New Products for the Ophthalmics franchise before the recent acquisition of Shire by Takeda. Prior to her time at Shire, Susan spent more than 10 years at Bausch and Lomb in a number of senior management roles, including sales, marketing, commercial operations, and business development. She also was Co-founder and Chief Commercial Officer for a biopharmaceutical startup, Sirion Therapeutics, that focused exclusively on the development and commercialization of ophthalmic pharmaceuticals. Ms. Benton brings decades of experience in the pharmaceutical and biotechnology industries, particularly in ophthalmology, with direct responsibility for the launch and commercialization of more than 15 products over the course of her career. In 2019, Susan was appointed to the Board of Directors for Tarsius Pharma, LTD and Translatum Medicus, Inc.
“We are delighted that Susan is joining Théa as our Country Manager for the USA,” said Jean-Frédéric Chibret, President of the Théa Group. “We have great confidence in her expertise to establish the company in the US and grow our business and product offering for the patients and the eye care professionals that care for them. Her experience in ophthalmology and her breadth of skills are of great value to Théa. We look forward to Susan’s leadership in sharing the Théa family-spirit and building strong relationships with our partners”.
Of her appointment, Ms. Benton remarked, “I am honored to be joining the Théa Team at such an important point in its history and look forward to building on its strengths in developing and commercializing innovative ophthalmic prescription and OTC products. Based on the existing product portfolio and pipeline of products in development, we have a clear opportunity to meet the needs of patients and their families as well as the clinicians who serve them.”
The establishment of Thea Pharma Inc. in the US adds to a list of over 70 countries around the world where Théa currently has a presence. An independent, family-owned pharmaceutical company, Théa aims to meet the needs of eye care professionals by covering all the therapeutic and OTC classes from allergy to glaucoma, dry eye, antibiotics, anti-inflammatories, mydriatics, and eyelid hygiene. Since its creation in 1994, the company has played an important role in the latest pharmacological advances in ophthalmology. In particular, Théa was the pioneer and remains the world leader in preservative-free eye care products, designed to respect the integrity of the ocular surface.
Thea Pharma Inc. is an independent pharmaceutical company specializing in the commercialization of eye care products. For the last 150 years, parent company Laboratoires Théa has been a global leader and pioneer in ophthalmology. By researching and developing treatments, providing information, and sharing knowledge with specialists around the world, we enable everyone to keep their eyes wide open.
Thea is an independent eye care group with a global presence, led by the Chibret family for 5 generations. The legacy of this highly respected ophthalmic endeavor is carried on today by Jean-Frédéric Chibret. We continue to serve the complex needs of eye care professionals as we extend our reach and bring our history of expertise and passion to the US.
IYUZEH™ (latanoprost ophthalmic solution) 0.005%, the first and only preservative-free formulation of latanoprost, the most prescribed prostaglandin F2α analogue (PGA), is now available in the U.S.
05/31/2023
The Glaucoma Foundation, The Intrepid Eye Society, National Medical Association Ophthalmology Section, and Real World Ophthalmology Unite with Thea to Help Preserve Patient Eye Health WALTHAM, Mass., May 30, 2023 /PRNewswire/ — Thea Pharma Inc. (“Thea”), the U.S. subsidiary of Europe’s leading independent ophthalmic-focused pharmaceutical company, Laboratoires Théa, today announced the launch of the Preservative Freedom Coalition to raise awareness of unmet […]
Thea Portfolio of Products Acquired from Akorn are not Affected by this Recall WALTHAM, Mass., April 28, 2023 /PRNewswire/ — Thea Pharma Inc. (“Thea”), the U.S. subsidiary of Europe’s leading independent pharmaceutical company, Laboratoires Théa, dedicated to the research, development, and commercialization of ophthalmic products, is responding to the recent statement related to the Akorn […]
LEXINGTON, Massachusetts – March 3, 2023 – Thea Pharma, Inc. (“Thea”), the U.S. subsidiary of Europe’s leading independent pharmaceutical company, Théa, dedicated to the research, development, and commercialization of ophthalmic products, announced the presentation of Phase III data on IYUZEH (latanoprost ophthalmic solution) 0.005% by Jason Bacharach, MD at the 2023 American Glaucoma Society (AGS) […]
IYUZEH™ (latanoprost ophthalmic solution) 0.005% is the first and only preservative-free formulation of latanoprost, the most prescribed prostaglandin F2α analogue (PGA) in the United States LEXINGTON, Massachusetts – December 14, 2022 – Thea Pharma, Inc. (“Thea”), the U.S. subsidiary of Europe’s leading independent pharmaceutical company, Laboratoires Théa, dedicated to the research, development and commercialization of ophthalmic products, […]
Théa Pharma announced the availability of the iVIZIA line of over-the-counter (OTC) eye care products in the United States. The iVIZIA OTC product line includes lubricating eye drops, lubricating eye gel, and three options for daily hygiene of sensitive eyelids. iVIZIA eye drops offer preservative-free extended relief and ocular surface protection to patients with any type of […]
LEXINGTON, MASSACHUSETTS – March 9, 2022 – Théa Pharma Inc. (“Théa”), the US subsidiary of Europe’s leading independent pharmaceutical company specializing in the research, development and commercialization of eye care products, today announced the completion of its previously announced acquisition of seven branded ophthalmic products from Akorn Operating Company LLC. The transaction expands Théa’s role […]
CLERMONT-FERRAND, FRANCE – January 28, 2022 – Laboratoires Théa SAS (“Théa”), Europe’s leading independent pharmaceutical company specializing in the research, development, and commercialization of eye-care products, today announced an agreement to purchase seven branded ophthalmic products from Akorn Operating Company LLC. The transaction will make Théa a best-in-class provider of products designed to fill the […]
Théa, the leading European pharmaceutical group in ophthalmology (excluding the retina market), increases its research and clinical trials capacity by doubling its innovation space footprint at the headquarters in Clermont-Ferrand.
03/07/2021
World Glaucoma Week (March 7-13) is a global initiative of the World Glaucoma Association (WGA) to raise awareness on glaucoma. Glaucoma is a chronic eye disease that has become the 2nd leading cause of blindness in the world.